NBIX Financial Facts
Deferred gain on real estate: 853KTotal operating expenses: 38.44M
See Full Income Statement
Total stockholders' equity: 351.65M
Total current assets: 357.89M
See Full Balance Sheet
Neurocrine Biosciences Inc. (NBIX) Earnings
|
Expand Research on NBIX
| Next EPS Date | 5/1/24 | EPS Growth Rate | +313.7% |
|---|---|---|---|
| Average EPS % Beat Rate | -13.2% | Revenue Growth Rate | +25.6% |
| Average % Move 1-Wk after EPS | -1.7% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/1/24  |
Q124 | N/A | $1.09 | N/A | N/A | $514.8M | N/A | N/A | N/A | ||
| 2/7/24 | Q423 | $1.54 | $1.21 | +$0.33 | $515.2M | $518.2M | N/A |  | | Details | |
| 10/31/23 | Q323 | $1.54 | $1.05 | +$0.49 | $498.8M | $478.85M | = | | | Details | |
| 8/1/23 | Q223 | $1.25 | $0.81 | +$0.44 | $452.7M | $446.75M | = | | | Details | |
| 5/3/23 | Q123 | -$0.51 | $0.63 | -$1.14 | $410M | $410.82M | = | | | Details | |
| 2/6/23 | Q422 | $1.24 | $1.12 | +$0.12 | $412M | $408.87M | = | | | Details | |
| 11/1/22 | Q322 | $1.08 | $0.80 | +$0.28 | $387.9M | $376.55M | N/A | | | Details | |
| 8/4/22 | Q222 | $0.43 | $0.62 | -$0.19 | $288.9M | $341.44M | N/A | | | Details |
